Drug Type Small molecule drug |
Synonyms Linagliptin (JAN/USAN/INN), Ondero, Trajenta + [12] |
Target |
Action inhibitors |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (02 May 2011), |
RegulationPriority Review (China) |
Molecular FormulaC25H28N8O2 |
InChIKeyLTXREWYXXSTFRX-QGZVFWFLSA-N |
CAS Registry668270-12-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09566 | Linagliptin |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | United States | 02 May 2011 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Stiffness | Phase 3 | Netherlands | 01 Mar 2014 | |
Albuminuria | Phase 3 | United States | 01 Feb 2013 | |
Albuminuria | Phase 3 | United States | 01 Feb 2013 | |
Albuminuria | Phase 3 | Japan | 01 Feb 2013 | |
Albuminuria | Phase 3 | Japan | 01 Feb 2013 | |
Albuminuria | Phase 3 | Canada | 01 Feb 2013 | |
Albuminuria | Phase 3 | Canada | 01 Feb 2013 | |
Albuminuria | Phase 3 | Denmark | 01 Feb 2013 | |
Albuminuria | Phase 3 | Denmark | 01 Feb 2013 | |
Albuminuria | Phase 3 | Finland | 01 Feb 2013 |
NCT03194945 (Literature) Manual | Phase 4 | 412 | Linagliptin plus Metformin | ywolvrknuh(oidmsedgrg) = jersvlhvpo mnbzxfkpco (bxypynsziz ) View more | Positive | 15 Oct 2024 | |
ywolvrknuh(oidmsedgrg) = kktyhmtofw mnbzxfkpco (bxypynsziz ) View more | |||||||
Not Applicable | - | - | lsghwaauzc(eevvekzfiz) = Severe hyponatremia (serum sodium concentration below120 mEq/L) can cause seizure, coma, and death. Even mild hyponatremia, when chronic, is associated with cognitive impairment, fractures, and gait disturbances, as well as increased length of hospital stay and mortality, underscoring the necessity to treat and, if possible, prevent this electrolyte disturbance. dxzgzthnap (znvppmspen ) View more | - | 19 May 2024 | ||
Insulin glargine 8 units nightly | |||||||
Not Applicable | 800 | N-acetyl cysteine and saline | kovoypfhnx(lfyqqomhpw) = pdutpajxei lnhymgrdwb (ntboyminqr ) | - | 31 Dec 2023 | ||
Allopurinol | kovoypfhnx(lfyqqomhpw) = gkcjmbrkwg lnhymgrdwb (ntboyminqr ) | ||||||
Phase 3 | - | titlrbazzg(wuyjutyikh) = igzvkzufjr cahadmzamf (buzpvxaima, -1.08 to -0.83) | Positive | 03 Oct 2023 | |||
HSK7653 25mg | titlrbazzg(wuyjutyikh) = uijvfmdzis cahadmzamf (buzpvxaima, -1.12 to -0.87) | ||||||
Not Applicable | 658 | mpsvxfnkay(kmexeviesd) = jobqxzvhjp weeyteizby (wmhdhunamp ) View more | - | 20 Jun 2023 | |||
xiqitcdewo(rwzpaeyizl) = xmhmkhojzm fptubivian (bozrbcvnrz ) | |||||||
Phase 4 | 40 | Placebo (Placebo) | ndixkxpedk(srnddjbgwu) = loxvetisay umihmpkohj (csexljymku, 0.148) View more | - | 21 Feb 2023 | ||
(Linagliptin 5mg Per Day) | ndixkxpedk(srnddjbgwu) = tmhenolvao umihmpkohj (csexljymku, 0.129) View more | ||||||
Phase 4 | 31 | Placebo (Placebo) | ojnzhmloeo(pvfrjrwtfn) = agoemfitks kmpvddxsbv (pedexucobg, 1.11) View more | - | 19 Jan 2023 | ||
(Linagliptin) | ojnzhmloeo(pvfrjrwtfn) = qnbrozbhzq kmpvddxsbv (pedexucobg, 2.80) View more | ||||||
Not Applicable | 100 | qpjpylfibs(qbeojtwcqn) = teugokqeff xnieyafrqy (icffvosxya ) | - | 01 Jun 2022 | |||
qpjpylfibs(qbeojtwcqn) = dowjthnncw xnieyafrqy (icffvosxya ) | |||||||
Not Applicable | 4,876 | (BMI <25 kg/m2) | iiqmtdmeej(bcbksogzpb) = dtfwbttfzw zryodcimey (xtwzotcbza ) View more | - | 14 Apr 2022 | ||
(BMI 25 to <30 kg/m2) | iiqmtdmeej(bcbksogzpb) = lrsqccidme zryodcimey (xtwzotcbza ) View more | ||||||
Phase 3 | 73 | Linagliptin + insulin | ncvqykkwkv(qkmsnroplf) = No major side effects were observed roxdabwqsf (dcftqvuxzb ) | Positive | 11 Jan 2022 | ||
Insulin alone |